Rashida Rahman, MD
Nephrology · Manassas, VANPI 1982631115
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,304, 3.7 times the $355 reported in 2019.
Across 245 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$559
- AstraZeneca$417
- Novartis$362
- Mallinckrodt Hospital Products Inc.$350
- OPKO Pharmaceuticals, LLC$289
- ANI Pharmaceuticals, Inc.$286
- plus $3K from 23 others
Across 133 payments — averaging $1806.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$140K
- Vertex$95K
- Boehringer Ingelheim International GmbH$6K
What the payments were for
- Food & beverage$4,83492%
- Education$4228%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 31 | $559 |
| AstraZeneca(2 entities) | 19 | $417 |
| Novartis | 19 | $362 |
| Mallinckrodt Hospital Products Inc. | 11 | $350 |
| OPKO Pharmaceuticals, LLC | 18 | $289 |
| ANI Pharmaceuticals, Inc. | 12 | $286 |
| Bayer | 17 | $274 |
| Ardelyx, Inc. | 12 | $261 |
| Akebia Therapeutics Inc | 12 | $258 |
| Boehringer Ingelheim | 6 | $241 |
| Amgen(2 entities) | 12 | $237 |
| Fresenius USA Marketing, Inc. | 19 | $236 |
| Travere Therapeutics, Inc. | 13 | $214 |
| Aurinia Pharma U.S., Inc. | 8 | $189 |
| Novo Nordisk | 4 | $176 |
| GSK | 6 | $155 |
| Otsuka America Pharmaceutical, Inc. | 6 | $142 |
| Medtronic | 1 | $136 |
| Xeris Pharmaceuticals, Inc. | 3 | $112 |
| Mallinckrodt Enterprises LLC | 3 | $67 |
| Calliditas Therapeutics US Inc. | 3 | $63 |
| Lilly USA, LLC | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $38 |
| Scpharmaceuticals Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $27 |
| Sanofi | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,256 in reported general payments places this provider in the 85th percentile of 298 nephrology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 81 | $70,902 |
| VelphoroSucroferric Oxyhydroxide | 24 | $70,794 |
| AuryxiaFerric Citrate | 25 | $58,330 |
| FarxigaDapagliflozin Propanediol | 58 | $53,708 |
| KerendiaFinerenone | 27 | $27,442 |
| EliquisApixaban | 14 | $14,186 |
| Calcium Acetate | 99 | $7,411 |
| Potassium Citrate ErPotassium Citrate | 14 | $2,965 |
| Cinacalcet Hcl | 14 | $1,578 |
| Valsartan | 59 | $1,549 |
| Allopurinol | 198 | $1,479 |
| Amlodipine Besylate | 220 | $1,078 |
| Hydralazine Hcl | 50 | $929 |
| Famotidine | 75 | $905 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 11 | $894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $241 | $70,90281 claims |
| Fresenius USA Marketing, Inc.Velphoro | $236 | $70,79424 claims |
| Akebia Therapeutics IncAuryxia | $258 | $58,33025 claims |
| AstraZenecaFarxiga | $417 | $53,70858 claims |
| BayerKerendia | $274 | $27,44227 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $286 | $1,54959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 298 nephrology providers in Virginia.
Other nephrology in Manassas
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Csaba KovesdySalem$152K
- Ramin TolouianNorfolk$115K
- Mahesh KrishnanMc Lean$115K
- Mitchell RosnerCharlottesville$105K
- Neeraja TandraReston$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.